Dr. Lyttle was appointed interim President and CEO in November 2013 and currently also serves as Chairman of the Scientific Advisory Board since June 2012. He previously served as President and CEO of Radius from September 2004 to December 2011 and interim Chief Scientific Officer from December 2011 to June 2012. Dr. Lyttle served as Executive Chairman of Karos Pharmaceuticals from July 2010 to November 2013. Previously, he was Vice President of Discovery for Women's Health and Bone as well as Head of the Women's Health Research Institute at Wyeth. At Wyeth, he directed drug discovery in women's health for several areas including menopause, contraception, reproductive disorders, osteoarthritis, osteoporosis, and urinary incontinence. Under his leadership, Wyeth advanced 17 new product candidates into preclinical and clinical development, including the SERM, bazedoxifene; Tanaproget, a novel non-steroidal contraceptive; and DVS-233 for vasomotor symptoms associated with menopause. Prior to joining Wyeth, Dr. Lyttle was Research Professor of Obstetrics, Gynecology, and Pharmacology at the University of Pennsylvania. He received a PhD in Biochemistry from Queen's University, Kingston, Ontario, followed by postdoctoral research at the Population Council at the Rockefeller University, and the University of Chicago.
Nick Harvey is Senior Vice President and Chief Financial Officer of Radius. He has more than 15 years of experience in building and financing life sciences and technology companies. Prior to joining Radius, he served for four years as Managing Director of Shiprock Capital, a venture capital firm, where he was responsible for deal-sourcing, negotiating and closing transactions, and developing strategic plans for portfolio companies. Before that, Mr. Harvey served as CFO of a number of venture-backed companies over a 10-year period, including Transfusion Technologies and Transcend Therapeutics. At Transfusion, he helped to close a major distribution agreement with Zimmer and oversaw the company's acquisition by Haemonetics. Mr. Harvey holds an undergraduate degree in Economics and a law degree with first-class honors from the Australian National University, and an MBA from the Harvard Business School.
Louis Brenner, MD, is Chief Medical officer of Radius. Prior to joining Radius, he served as Senior Vice President at AMAG Pharmaceuticals, where he was responsible for the Phase 3 studies and the successful regulatory submission for Feraheme®. Before that, he served in progressively senior roles at Genzyme, where he advanced the development and commercialization of products to treat metabolic bone disease.He is the co-inventor of the formulation for Renvela®, an oral phosphate binder to treat hyperphosphatemia, and lead the acquisition of Bone Care International, manufacturer of Hectorol®, a synthetic Vitamin D analog for the treatment of hyperparathyroidism. He also previously served as a Director of PLC Medical Systems. Dr. Brenner is board-certified in Nephrology and cares for patients at Brigham and Women's Hospital in Boston, and is a lecturer in Medicine at Harvard Medical School. He received a BS in Biology from Yale University, an MD from Duke University, and an MBA from Harvard Business School.
Dr. Hattersley is Senior Vice President, Preclinical Development at Radius. He has more than 20 years of experience in musculoskeletal research and is the author of numerous scientific publications related to bone biology and physiology. Prior to joining Radius, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals with responsibility for the discovery and development of novel small-molecule agents for the treatment of osteoporosis and other metabolic bone diseases. Dr. Hattersley also held positions at Genetics Institute/Wyeth Research investigating the application of the bone morphogenetic proteins in bone and connective tissue repair and regeneration. Dr. Hattersley received a PhD in Experimental Pathology from St. George's Hospital Medical School in London.